Login / Signup

Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong.

Herbert Ho-Fung LoongCarlos K H WongLinda K S LeungCatherine P K ChanAndrea ChangZheng-Yi ZhouJipan XieMeaghan Gibbs
Published in: Cost effectiveness and resource allocation : C/E (2020)
Ceritinib offers a cost-effective option compared to crizotinib for previously untreated ALK + advanced NCSLC in HK.
Keyphrases
  • advanced non small cell lung cancer
  • epidermal growth factor receptor
  • tyrosine kinase
  • diffuse large b cell lymphoma
  • protein kinase
  • high glucose
  • endothelial cells